$CTMX

Cantor Fitzgerald reiterated an Overweight rating on CytomX Therapeutics (CTMX) with a $12 price target, citing a potential inflection point. Shares are down 40% YTD, trading at $2.42. The company reported a wider-than-expected Q2 2026 loss and revenue decline, but noted promising early drug data and substantial cash reserves. Guggenheim lowered its price target to $14, maintaining a Buy rating.

CytomX Therapeutics (CTMX) announced FDA Fast Track Designation for Varseta-M, a treatment for relapsed/refractory metastatic colorectal cancer. The designation follows encouraging Phase 1 data. A potential monotherapy registrational study is planned for initiation in 1H 2027, according to the company.

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001501989 0001501989 2026-07-24 2026-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24,

CytomX Therapeutics, Inc. (CTMX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 3 d154321dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 CYTOMX THERAPEUTICS, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN Amended and Restated: March 19, 2025 Approved by Stockholders: June 11, 2025 (as Amended by the Board: March 18, 2026) I. INTRODUCTION 1.1 Purposes .

CytomX Therapeutics (CTMX) announced that its experimental cancer drug, CX-801, has entered a key early-phase clinical trial (CTMX-801-101) for advanced solid tumors. The study, conducted alone and in combination with Merck's Keytruda, aims to assess safety, dosage, and initial anti-tumor activity. This development emphasizes CytomX's strategic focus on the solid tumor market and could significantly influence investor sentiment as trial data emerges.

Wall Street Zen has downgraded CytomX Therapeutics (NASDAQ:CTMX) from "sell" to "strong sell" following the company's Q1 earnings miss and significant insider stock sales. Despite this, the broader analyst community maintains a "Moderate Buy" consensus with a higher average price target, suggesting a divergence in outlooks. The report highlights CTMX's recent financial performance, insider activity, and institutional ownership, contrasting it with other analysts' more optimistic ratings and price targets.

The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of CytomX Therapeutics Inc (CTMX) common stock as of March 13, 2026. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries began reporting beneficial ownership separately, as permitted by SEC Release No. 34-39538. The filing indicates no voting or dispositive power over CTMX shares for The Vanguard Group itself.

Barclays has increased its price target for CytomX Therapeutics, Inc. (CTMX) to $10 from $8 while maintaining an Overweight rating, following a similar move by Piper Sandler and new coverage initiation by Guggenheim with a Buy rating, both also setting a $10 price target. The positive outlook is primarily driven by promising Phase I data on varsetatug maseatecan, which demonstrated significant anti-tumor activity in metastatic colorectal cancer patients. CytomX is expected to provide further updates on its expansion cohorts soon.

CytomX Therapeutics' stock has reached a 52-week high of $6.16, marking a 624.91% increase over the past year and pushing its market capitalization over $1 billion. Despite a recent decline in Q3 2025 revenue and a larger-than-expected loss per share, analyst price targets range from $6 to $10, reflecting continued optimism about the company's drug pipeline and future growth. Investors are paying a premium, with the stock trading at a P/E ratio of 24.98 according to InvestingPro data, though RSI suggests it might be overvalued.